Celsius stock has experienced a significant decline, with competition from Costco spooking investors. The company is still in early stages of international expansion. The article examines whether this drop presents a buying opportunity for investors.

Celsius stock has fallen 21% over six trading days due to Costco's entry into the energy drink market and broader market weakness. However, analysts argue the selloff is overdone. The article highlights three reasons for optimism: Costco's Kirkland Signature drinks lack Celsius's weight-loss benefits and have limited distribution, Celsius has strong growth momentum with the Alani Nu acquisition, and the stock trades at a reasonable valuation of 16x next year's earnings despite consistent earnings beat performance.

Celsius Holdings stock has plummeted 49% from its 52-week high to $34 per share, primarily due to Costco launching a cheaper private-label energy drink competitor. While the company reported strong Q4 sales of $722 million and successful acquisitions of Alani Nu and Rockstar Energy, the analyst remains cautious due to valuation concerns and intense competitive pressures in the beverage market. Despite impressive growth, the stock's forward P/E ratio in the twenties doesn't justify the risks in an increasingly competitive environment.

Celsius Holdings is positioned for significant growth with 86% full-year sales growth in 2025, driven by an expanded partnership with PepsiCo in North America and early-stage international expansion. The company's international business, though currently small at $93 million in sales, represents a major growth opportunity as it expands into new markets like Spain.

MIG Capital sold $37.41 million worth of Sotera Health shares (2.26 million shares) in Q4 2025, reducing its stake to 5.88% of AUM. Despite the trim, the fund maintains a significant position in the sterilization and lab testing company. Sotera posted its 20th consecutive year of revenue growth with 5.7% sales increase to $1.16 billion in 2025, while net income nearly doubled to $78 million. The company projects 5-6.5% revenue growth for 2026.

Celsius (CELH) has delivered a spectacular 6,300% return over the past decade through strong revenue growth, strategic acquisitions (Alani Nu and Rockstar Energy), and a PepsiCo distribution partnership. However, the bull case faces headwinds from intense competition with Red Bull and Monster Beverage commanding larger market shares, a lack of durable competitive moat, expensive valuation at 28.4x forward P/E, and analyst expectations for only 10% annual earnings growth through 2028. The author concludes the stock is not a buy at current levels.

Ten large-cap stocks experienced significant declines during the week of March 2-6, 2026, driven by weak earnings, lowered guidance, geopolitical tensions, rising yields, and AI-spending concerns. Notable losers include Lumentum Holdings (down 24.65%), Corning (down 21.91%), MongoDB (down 16.23%), and Celsius Holdings (down 17.86%), among others.

Celsius Holdings achieved a $2.5 billion revenue record in Q4 2025, driven primarily by its acquisition of Alani Nu, which generated over $1 billion in annual revenue. While core Celsius brand growth slowed to 7.5% due to high domestic market penetration, the Alani Nu acquisition has become the company's new growth engine, establishing Celsius as a multi-brand platform strategy.

The oral nicotine pouch market is projected to surge from $5.4 billion in 2024 to over $25 billion by 2030, driven by consumer shift toward tobacco-free and functional beverage formats. Major players including Celsius Holdings, British American Tobacco, Turning Point Brands, and Keurig Dr Pepper are expanding their portfolios with innovative energy and oral pouch products to capture growing demand for portable, controlled-dose stimulant delivery systems.

Celsius stock has more than doubled over the past year, driven by strong growth from its Alani Nu acquisition. The company reported 117% sales growth to $721.6 million and 86% EPS growth to $0.26, earning a double upgrade from Bank of America to 'buy.' With expected shelf space gains and margin improvements ahead, the stock trades at a reasonable 34x forward P/E, though investors should exit once distribution gains plateau.

An investor explains why they continue buying shares of PepsiCo, Main Street Capital, and Verizon, highlighting their strong dividend yields (3.8%-6.9%), consistent dividend growth records, and reliable cash flows that support passive income generation and financial independence.

The global consumer healthcare market is experiencing a structural shift where regulatory compliance and FDA approval have become critical competitive advantages. Major companies including Philip Morris, Celsius Holdings, USANA Health Sciences, and Medifast are advancing strategic initiatives focused on regulatory readiness, product integration, and market expansion. Doseology Sciences has partnered with McKinney Regulatory Science Advisors to strengthen its FDA pathway for oral pouch products.